Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Dudley J. Pennell; John B. Porter; Maria Domenica Cappellini; Lee Lee Chan; Amal El-Beshlawy; Yesim Aydinok; Hishamshah Ibrahim; Chi Kong Li; Vip Viprakasit; Mohsen Saleh Elalfy; Antonis Kattamis; Gillian Smith; Dany Habr; Gabor Domokos; Bernard Roubert; Ali Taher

doi:10.3324/haematol.2010.031468

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to

Original language	English
Pages (from-to)	48-54
Number of pages	7
Journal	Haematologica
Volume	96
Issue number	1
DOIs	https://doi.org/10.3324/haematol.2010.031468
Publication status	Published - Jan 2011

Keywords

β-thalassemia major
Cardiac iron overload
Deferasirox
Iron chelation
Myocardial T2*

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2010.031468

Cite this

Pennell, D. J., Porter, J. B., Cappellini, M. D., Chan, L. L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C. K., Viprakasit, V., Elalfy, M. S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., & Taher, A. (2011). Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica, 96(1), 48-54. https://doi.org/10.3324/haematol.2010.031468

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. / Pennell, Dudley J.; Porter, John B.; Cappellini, Maria Domenica; Chan, Lee Lee; El-Beshlawy, Amal; Aydinok, Yesim; Ibrahim, Hishamshah; Li, Chi Kong; Viprakasit, Vip; Elalfy, Mohsen Saleh; Kattamis, Antonis; Smith, Gillian; Habr, Dany; Domokos, Gabor; Roubert, Bernard; Taher, Ali.

In: Haematologica, Vol. 96, No. 1, 01.2011, p. 48-54.

Research output: Contribution to journal › Article › peer-review

Pennell, DJ, Porter, JB, Cappellini, MD, Chan, LL, El-Beshlawy, A, Aydinok, Y, Ibrahim, H, Li, CK, Viprakasit, V, Elalfy, MS, Kattamis, A, Smith, G, Habr, D, Domokos, G, Roubert, B & Taher, A 2011, 'Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload', Haematologica, vol. 96, no. 1, pp. 48-54. https://doi.org/10.3324/haematol.2010.031468

Pennell, Dudley J. ; Porter, John B. ; Cappellini, Maria Domenica ; Chan, Lee Lee ; El-Beshlawy, Amal ; Aydinok, Yesim ; Ibrahim, Hishamshah ; Li, Chi Kong ; Viprakasit, Vip ; Elalfy, Mohsen Saleh ; Kattamis, Antonis ; Smith, Gillian ; Habr, Dany ; Domokos, Gabor ; Roubert, Bernard ; Taher, Ali. / Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. In: Haematologica. 2011 ; Vol. 96, No. 1. pp. 48-54.

@article{b5b43d3992ca4be091f6d4fdd34027be,

title = "Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload",

abstract = "Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to ",

keywords = "β-thalassemia major, Cardiac iron overload, Deferasirox, Iron chelation, Myocardial T2*",

author = "Pennell, {Dudley J.} and Porter, {John B.} and Cappellini, {Maria Domenica} and Chan, {Lee Lee} and Amal El-Beshlawy and Yesim Aydinok and Hishamshah Ibrahim and Li, {Chi Kong} and Vip Viprakasit and Elalfy, {Mohsen Saleh} and Antonis Kattamis and Gillian Smith and Dany Habr and Gabor Domokos and Bernard Roubert and Ali Taher",

year = "2011",

month = jan,

doi = "10.3324/haematol.2010.031468",

language = "English",

volume = "96",

pages = "48--54",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "1",

}

TY - JOUR

T1 - Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

AU - Pennell, Dudley J.

AU - Porter, John B.

AU - Cappellini, Maria Domenica

AU - Chan, Lee Lee

AU - El-Beshlawy, Amal

AU - Aydinok, Yesim

AU - Ibrahim, Hishamshah

AU - Li, Chi Kong

AU - Viprakasit, Vip

AU - Elalfy, Mohsen Saleh

AU - Kattamis, Antonis

AU - Smith, Gillian

AU - Habr, Dany

AU - Domokos, Gabor

AU - Roubert, Bernard

AU - Taher, Ali

PY - 2011/1

Y1 - 2011/1

N2 - Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to

AB - Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to

KW - β-thalassemia major

KW - Cardiac iron overload

KW - Deferasirox

KW - Iron chelation

KW - Myocardial T2

UR - http://www.scopus.com/inward/record.url?scp=78650996705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650996705&partnerID=8YFLogxK

U2 - 10.3324/haematol.2010.031468

DO - 10.3324/haematol.2010.031468

M3 - Article

C2 - 21071497

AN - SCOPUS:78650996705

VL - 96

SP - 48

EP - 54

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this